Yale Jen Analyst PerformanceSenior Managing Director, Senior Biotech Analyst at LaidlawYale Jen is a stock analyst at Laidlaw in the healthcare sector, covering 11 publicly traded companies. Over the past year, Yale Jen has issued 5 stock ratings, including buy and hold recommendations. While full access to Yale Jen's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Yale Jen's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access to unlock analyst rankings MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings12 Last 11 YearsBuy Recommendations91.67% 11 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution12RatingsDistribution of strong buy, buy, hold, and sell ratings by Yale Jen.RatingPercentageCount Strong Buy0.0%0 ratings Buy91.7%11 ratings Hold8.3%1 ratings Sell0.0%0 ratingsOut of 12 total stock ratings issued by Yale Jen at Laidlaw, the majority (91.7%) have been Buy recommendations, followed by 8.3% Hold.Best & Worst CallsBest Call000.0%AFMDJul 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%SNTIJun 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ90.9% of companies on NASDAQ10 companiesNYSEAMERICAN9.1% of companies on NYSEAMERICAN1 companyYale Jen, an analyst at Laidlaw, currently covers 11 companies listed on NASDAQ and NYSEAMERICAN, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare11 companies100.0%Yale Jen of Laidlaw specializes in stock coverage within the Healthcare sector.Coverage IndustriesIndustryPercentageBIOTECHNOLOGY5 companies45.5%PHARMACEUTICALS4 companies36.4%HEALTHCARE EQUIPMENT & SUPPLIES2 companies18.2% About Yale JenDr. Jen joined Laidlaw & Co. in September 2013 as Managing Director, Biotechnology Analyst. He has over ten years of Wall Street healthcare analyst experience. Prior to joining Laidlaw, he was a Senior Equity Analyst at Roth Capital Partners focusing on biotechnology since February 2012; and before that – a Senior Equity Analyst focusing on biotechnology and China healthcare at Maxim Group since November 2007. Prior, he was an associate analyst at Rodman and Renshaw and Thomas Weisel Partners covering large as well as mid to small cap biotechnology and specialty pharmaceutical companies. His investment views have been cited in the Wall Street Journal, Bloomberg, Thomson Reuters and Dow Jones Newswire. Before joining Wall Street, Yale spent several years with KPMG Corporate Finance Life Sciences Group and Genesis Group Associates focusing on mergers and acquisitions of healthcare assets, as well as on pipeline optimization for pharmaceutical and biotechnology clients. Dr. Jen received his Ph.D. in molecular biology from Cornell Medical School and his MBA from Rutgers University with a concentration in finance. He holds FINRA licenses: 7, 63, 86 and 87.Follow on LinkedIn Yale Jen's Ratings History at Laidlaw Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter More filters Fewer filters Done 0 Results Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsEYPTEyepoint Pharmaceuticals10/20/2026Downgrade$0.45Hold$0.0000.00% ROINCELNLS Pharmaceutics7/13/2026Initiated Coverage$4.19$23.00Buy$0.0000.00% ROIKZIANovogen4/15/2026Initiated Coverage$9.46$25.00Buy$0.0000.00% ROIPTNPalatin Technologies12/12/2025Initiated Coverage$24.67$60.00Buy$0.0000.00% ROIFEMYFemasys11/20/2025Initiated Coverage$15.18$130.00Buy$0.0000.00% ROISNTISenti Biosciences6/6/2025Initiated Coverage$3.56$5.00Buy$0.0000.00% ROISLNOSoleno Therapeutics3/27/2025Boost Price Target$68.01$105.00Buy$00.0000.00% ROINVCTNuvectis Pharma3/17/2025Initiated Coverage$8.85$19.00Buy$0.0000.00% ROILFWDLifeward2/10/2025Initiated Coverage$16.80$120.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche BankBMO Capital Markets Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.